11 November 2022
EMA/PDCO/850696/2022
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 11-14 October 2022

Chair: Brian Aylward – Vice-Chair: Sabine Scherer

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO opinion is adopted), and on the opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chair opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) pandemic, and the associated EMA Business Continuity Plan (BCP), the meeting was held in-person with some members connected remotely (hybrid setting).

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair welcomed the new member and alternate to the Committee.

1.2. Adoption of agenda

The agenda for 11-14 October 2022 meeting was adopted.

1.3. Adoption of the minutes

The minutes for 06-09 September 2022 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Cedirogant - EMEA-003142-PIP02-21

AbbVie Ltd; Treatment of psoriasis

Day 120 opinion

Dermatology

Note: Withdrawal request received on 17 October 2022

2.1.2. Ruxolitinib (phosphate) - EMEA-002618-PIP03-21

Incyte Biosciences Distribution B.V.; Treatment of atopic dermatitis

Day 120 opinion

Dermatology

Summary of Committee discussion:

The PDCO adopted a positive opinion for this PIP for the treatment of atopic dermatitis. A waiver was agreed for the paediatric population from birth to less than 3 months of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments. A deferral was granted for the completion of the PIP.

2.1.3. Sirolimus - Orphan - EMEA-003168-PIP01-21

Desitin Arzneimittel GmbH; Treatment of tuberous sclerosis

Day 120 opinion

Dermatology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for sirolimus for treatment of tuberous sclerosis was adopted. The PDCO agreed on a waiver in a subset of children less than 2 years of age on the grounds of lack of significant therapeutic benefit. The PDCO granted a deferral for the completion of this PIP.

2.1.4. Manganese chloride tetrahydrate - EMEA-003035-PIP02-21

Ascelia Pharma AB; Diagnostic evaluation of liver lesions by magnetic resonance imaging (MRI)

Day 120 opinion

Diagnostic

Summary of Committee discussion:

Having reviewed the conclusions reached at Day 90, the PDCO considered all outstanding issues resolved and agreed with the modified paediatric investigation plan.
A positive opinion of the Paediatric Committee on the agreement of a paediatric investigation plan for the condition "diagnostic evaluation of liver lesions by magnetic resonance imaging (MRI)", and a deferral, and a waiver for the paediatric population from birth to less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible, has been

adopted accordingly.

2.1.5. Glucagon analogue linked to a human immunoglobulin Fc fragment - Orphan - EMEA-003170-PIP01-21

Hanmi Pharm. Co., Ltd.; Treatment of congenital hyperinsulinism

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, a positive opinion was adopted by the PDCO for the PIP for glucagon analogue linked to a human immunoglobulin Fc fragment for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of congenital hyperinsulinism.

2.1.6. Semaglutide - EMEA-001441-PIP07-21

Novo Nordisk A/S; Treatment of obesity

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion was adopted for the PIP for the proposed medicine for children and adolescents from 6 years to less than 18 years of age in the condition of treatment of obesity. The PDCO agreed on a waiver in children from birth to less than 6 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments. The PDCO granted a deferral for the completion of this PIP.

2.1.7. Batoclimab - EMEA-003162-PIP01-21

Immunovant Sciences, GmbH; Treatment of myasthenia gravis

Day 120 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 2 years to less than 18 years of age, in the condition of treatment of myasthenia gravis was adopted. The PDCO agreed on a waiver in a subset of children on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset. The PDCO granted a deferral for the completion of this PIP.

2.1.8. Exenatide (acetate) - Orphan - EMEA-003183-PIP02-22

Invex Therapeutics Ltd; Treatment of idiopathic intracranial hypertension

Day 120 opinion

Neurology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issue raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for exenatide (acetate) for post-pubertal males and females less than 18 years of age, in the condition treatment of idiopathic intracranial hypertension was adopted.
The PDCO agreed on a waiver in the pre-pubertal males and females subset of the paediatric population on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.
The PDCO granted a deferral for the completion of this PIP.

2.1.9. Camidanlumab tesirine - EMEA-003160-PIP01-21

ADC Therapeutics SA; Treatment of Hodgkin lymphoma

Day 120 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for camidanlumab tesirine for paediatric patients from 3 years to less than 18 years of age with relapsed or refractory classical Hodgkin lymphoma (cHL), who have received at least 3 prior lines of systemic therapy, was adopted. The PDCO agreed on a waiver in a subset of children less than 3 years of age on the grounds of lack of significant therapeutic benefit. The PDCO granted a deferral for the completion of this PIP.

2.1.10. Emactuzumab - Orphan - EMEA-003172-PIP01-21

Synox Therapeutics Limited; Treatment of tenosynovial giant cell tumour, local and diffuse type

Day 120 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for the age subset from 12 years to less than 18 years of age, in the condition of treatment of tenosynovial giant cell tumour, local and diffuse type was adopted. The PDCO agreed on a waiver in a subset of children on the grounds that the specific medicinal product is likely to

be unsafe.

2.1.11. Efavaleukin alfa - EMEA-003156-PIP02-22

Amgen Europe B.V.; Treatment of ulcerative colitis

Day 120 opinion

Other

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children and adolescents from 2 years to less than 18 years of age, in the condition of treatment of ulcerative colitis was adopted. The PDCO agreed on a waiver in a subset of children from birth to less than 2 years of age on the grounds of lack of significant therapeutic benefit over existing treatments. The PDCO granted a deferral for the completion of this PIP.

2.1.12. Derivative of 3-phenyl-3H,4H,6H,7H-pyrano[3,4-d]imidazol-4-one - EMEA-003165-PIP01-21

Boehringer Ingelheim International GmbH; Treatment of chronic kidney disease

Day 120 opinion

Uro-nephrology

Summary of Committee discussion:

Having reviewed the conclusions reached at Day 90, the PDCO considered all outstanding issues resolved and agreed with the modified paediatric investigation plan. A positive opinion has been adopted accordingly for derivative of 3-phenyl-3H,4H,6H,7H-pyrano[3,4-d]imidazole-4-one (BI 690517) for the treatment of children from 6 months of age with chronic kidney disease. A waiver was granted up to 6 months of age on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). A deferral for one or more measures contained in the paediatric investigation plan was agreed.

2.1.13. Pneumococcal polysaccharide serotype 35B – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 31 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 24F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 23B – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 23A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 16F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 15C – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 15A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 20 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 17F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 12F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 11A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 10A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 9N – diphtheria CRM197 conjugate /

Pneumococcal polysaccharide serotype 8 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 33F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 22F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 19A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 7F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 6A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 3 – diphtheria CRM197 conjugate - EMEA-003155-PIP01-21

Merck Sharp & Dohme (Europe), Inc.; Prevention of disease caused by *Streptococcus pneumoniae*

Day 120 opinion

Vaccines

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion was adopted for Pneumococcal polysaccharide serotype 3 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 8 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 15C – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 6A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 15A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 16F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 19A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 23A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 24F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 17F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 33F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 10A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 12F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 20 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 31 – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 35B – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 7F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 22F – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 9N – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 11A – diphtheria CRM197 conjugate / Pneumococcal polysaccharide serotype 23B – diphtheria CRM197 conjugate in children from 2 years to less than 18 years of age in the condition of 'prevention of disease caused by *Streptococcus pneumoniae*'.
The PDCO agreed on a waiver in children from birth to less than 6 months of age on the grounds that the specific medicinal product is likely to be ineffective and in children from 6 months to less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.
The PDCO granted a deferral for the completion of this PIP.

2.1.14. COVID-19 Vaccine (recombinant, adjuvanted) - EMEA-003191-PIP01-22

HIPRA Human Health S.L.U.; Prevention of coronavirus disease 2019 (COVID-19)

Day 120 opinion

Vaccines / Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, including on the responses provided by the applicant to the outstanding questions raised at Day 90, the PDCO agreed on a paediatric investigation plan with a deferral for COVID-19 vaccine (recombinant, adjuvanted) for all subsets of the paediatric population from birth to less than 18 years of age in the condition of prevention of coronavirus disease 2019 (COVID-19).
The PIP contains one quality study for the development of a lower strength formulation for paediatric use, and three clinical studies aimed at safety and immunogenicity. A primary vaccination series is pursued in children below 5 years of age while above this age the vaccine will be studied for use as heterologous booster.

2.1.15. Tigulixostat - EMEA-003272-PIP01-22

LG Chem, Ltd.; Treatment of hyperuricemia

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO discussed at Day 60, during the October 2022 plenary meeting, an application for a waiver for tigulixostat for treatment of hyperuricemia in primary gout. The PDCO considered clarifications submitted by the applicant between D30 and D60. The applicant agreed to broadening of the indication to 'treatment of hyperuricemia'. The applicant admitted that there is potential for off label use of tigulixostat in very rare cases. However, the arguments for the lack of study feasibility was presented and accepted by the PDCO.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for tigulixostat for all subsets of the paediatric population (from birth to 18 years of age) in the condition of treatment of hyperuricemia.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid - Orphan - EMEA-003282-PIP01-22

Horizon Therapeutics Ireland DAC; Treatment of systemic sclerosis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for 2-[4-methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of systemic sclerosis on the grounds that that the disease or

condition for which the specific medicinal product is intended does not occur in children.
The PDCO recommended to grant the waiver for all pharmaceutical forms and all routes of administration to which the applicant agreed.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.17. Namilumab - EMEA-003275-PIP01-22

Kinevant Sciences GmbH; Treatment of sarcoidosis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition of treatment of sarcoidosis on the grounds that the disease does not occur in the specified paediatric subset, and on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.18. Nipocalimab - EMEA-002559-PIP06-22

Janssen-Cilag International NV; Treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Day 60 opinion

Neurology

Summary of Committee discussion:

The PDCO confirmed the outcome of Day 30 discussion. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant´s request for a waiver.
The PDCO recommended granting a waiver for nipocalimab for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition of treatment of chronic inflammatory demyelinating polyradiculoneuropathy on the grounds that the specific medicinal product is likely to be unsafe in part of the paediatric population (up to 2 years of age) and on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients (2-18 years of age).

2.1.19. 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one - EMEA-003278-PIP01-22

Novartis Europharm Limited; Treatment of lung cancer (small cell and non-small cell lung cancer)

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60 during the October 2022 plenary meeting a request for a product-specific waiver for 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (JDQ443) for the treatment of non-small cell lung cancer (NSCLC) and the treatment of small cell lung cancer on the grounds that the disease for which the specific medicinal product is intended occurs only in adult populations.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of "treatment of lung cancer (small cell and non-small cell lung cancer)" on the grounds that the disease does not (virtually) exist in children.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.

2.1.20. Cobolimab - EMEA-003273-PIP01-22

GlaxoSmithKline Trading Services Limited; Treatment of lung cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for cobolimab for all subsets of the paediatric population (birth to less than 18 years of age) in the condition of treatment of lung cancer. Since the agreed waiver ground is that the disease does not occur in the paediatric population, the possibility to apply this to all pharmaceutical forms and all routes of administrations was agreed to by the applicant.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.21. Lacutamab - Orphan - EMEA-003281-PIP01-22

Innate Pharma SA; Treatment of cutaneous T cell lymphoma

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60 during the October 2022 plenary meeting a request for a product-specific waiver for lacutamab for the treatment of cutaneous T cell lymphoma on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of "treatment of cutaneous T cell lymphoma" on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.22. Pemigatinib - Orphan - EMEA-002370-PIP03-22

Incyte Biosciences Distribution B.V.; Treatment of myeloid / lymphoid neoplasms with eosinophilia and gene rearrangement

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60 during the October 2022 plenary meeting a request for a product-specific waiver for pemigatinib for the treatment of myeloid / lymphoid neoplasms on the grounds that pemigatinib is likely to be unsafe and on the grounds of lack significant therapeutic benefit in the entire paediatric population.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of "treatment of myeloid / lymphoid neoplasms with eosinophilia and gene rearrangement" on the grounds of lack of significant therapeutic benefit as clinical studies would not be feasible.

2.1.23. Vusolimogene oderparepvec - EMEA-003265-PIP01-22

Replimune, Inc.; Treatment of cutaneous squamous cell carcinoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee including contributions of external expert(s), the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed product for all subsets of the paediatric population (0 to less than 18 years of age) in the condition of cutaneous squamous cell carcinoma based on the grounds that the disease does not occur in the specified paediatric subsets.

2.1.24. 2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol - EMEA-003269-PIP01-22

Blueprint Medicines (Netherlands) B.V.; Treatment of mastocytosis

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO discussed at Day 60, during the October 2022 plenary meeting, an application for a waiver for 2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol for the treatment of mastocytosis.
Based on the assessment of this application, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for 2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol for all subsets of the paediatric population (from birth to 18 years of age) in the condition of treatment of mastocytosis.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

2.2.1. Dopamine (hydrochloride) - EMEA-C-001105-PIP01-10-M06

BrePco Biopharma Limited; Treatment of vascular hypotensive disorders

Day 60 opinion

Neonatology - Paediatric Intensive Care

Summary of Committee discussion:

The PDCO has discussed this procedure on D60, having taken into account clarifications and additional information provided by the applicant after D30, and adopted on 14 October 2022 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's decision (P/0209/2022) of 10 June 2022.

2.2.2. Brivaracetam - EMEA-C-000332-PIP01-08-M16

UCB Pharma S.A.; Treatment of epilepsy with partial onset seizures

Day 60 opinion

Neurology

Summary of Committee discussion:

The PDCO confirmed the full compliance.

2.2.3. Eladocagene exuparvovec - EMEA-C-002435-PIP01-18-M02

PTC Therapeutics International Limited; Treatment of aromatic L-amino acid decarboxylase deficiency

Day 60 opinion

Neurology

Note: Withdrawal request received on 13 October 2022

2.2.4. Vosoritide - EMEA-C4-002033-PIP01-16-M02

BioMarin International Limited; Treatment of achondroplasia

Day 60 letter

Other

Summary of Committee discussion:

The PDCO discussed the completed study and considered that it is compliant with the latest Agency's decision (P/0051/2022) of 11 March 2022.

2.2.5. Agomelatine - EMEA-C-001181-PIP01-11-M06

Les Laboratoires Servier; Treatment of major depressive episodes

Day 60 opinion

Psychiatry

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001181-PIP01-11

The Committee adopted on 14 October 2022 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's decision (P/0115/2021) of 17 March 2021.

2.2.6. Maralixbat chloride - EMEA-C-001475-PIP02-13-M02

Mirum Phamraceuticals; Treatment of Alagille syndrome

Day 30 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001475-PIP02-13-M01

The PDCO adopted on 11 October 2022 an opinion confirming the compliance of all studies

in the agreed paediatric investigation plan as set out in the latest Agency's decision (P/0298/2022) of 10 August 2022.

2.2.7. Dabrafenib - EMEA-C-001147-PIP02-20

Novartis Europharm Limited; Treatment of glioma

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO adopted the opinion by written procedure on 27 September 2022.

2.2.8. Trametinib - EMEA-C-001177-PIP02-20

Novartis Europharm Limited; Treatment of glioma

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO adopted the opinion by written procedure on 27 September 2022.

2.2.9. Eculizumab - EMEA-C-000876-PIP05-15-M05

Alexion Europe SAS; Treatment of myasthenia gravis

Day 30 opinion

Neurology

Summary of Committee discussion:

The PDCO adopted on 14 October 2022 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's decision (P/0074/2022) of 11 March 2022.
The PDCO considers that the following studies could be considered significant:
Study 1 (ECU-MG-303), Study 2 and Study 3.

2.2.10. Omaveloxolone - EMEA-C1-002487-PIP01-18

Reata Ireland Limited; Treatment of Friedreich's ataxia

Day 30 letter

Other

Summary of Committee discussion:

The PDCO discussed this partial compliance check and concluded that despite some PK parameters not being collected as described in the key elements, the overarching objective can be considered met. The study was hence considered compliant.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Birch bark extract - EMEA-001299-PIP01-12-M01

Amryt AG; Treatment of skin injuries

Day 60 opinion

Dermatology

Note: Withdrawal request received on 29 September 2022

2.3.2. Brodalumab - EMEA-001089-PIP02-13-M03

LEO Pharma A/S; Treatment of psoriasis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0386/2021 of 8 September 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Glycopyrronium bromide - EMEA-002383-PIP01-18-M02

Dr. August Wolff GmbH & Co. KG - Arzneimittel; Treatment of hyperhidrosis

Day 60 opinion

Dermatology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0565/2021 of 21 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Gadoquatrane - EMEA-002778-PIP01-20-M01

Bayer AG; Diagnosis by evaluation of any known or suspected clinical condition with contrast enhanced magnetic resonance imaging

Day 60 opinion

Diagnostic

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0371/2020 of 23 October 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Inclisiran sodium - EMEA-002214-PIP01-17-M01

Novartis Europharm Ltd.; Treatment of elevated cholesterol

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0321/2018 of 12 September 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Saxagliptin - EMEA-000200-PIP01-08-M10

AstraZeneca AB; Treatment of type 2 diabetes

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0106/2022 of 13 April 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Vedolizumab - EMEA-000645-PIP04-20-M01

Takeda Pharma A/S; Treatment of pouchitis

Day 60 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0186/2021 of 10 May 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Recombinant human A disintegrin and metalloprotease with thrombospondin type-1Motifs 13 (rADAMTS13) - Orphan - EMEA-001160-PIP01-11-M03

Baxalta Innovations GmbH; Treatment of thrombotic thrombocytopenic purpura

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0414/2021 of 29 October 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.9. Voxelotor - Orphan - EMEA-002356-PIP02-20-M01

Global Blood Therapeutics Netherlands B. V.; Treatment of sickle cell disease

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0489/2020 of 21 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Risankizumab - EMEA-001776-PIP01-15-M01

AbbVie Ltd; Treatment of psoriasis

Day 60 opinion

Immunology-Rheumatology-Transplantation / Dermatology / Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that proposed changes to the statistical

plan for Study 2 could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0205/2016 of 4 August 2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Bedaquiline (fumarate) - Orphan - EMEA-000912-PIP01-10-M06

Janssen-Cilag International NV; Treatment of multi-drug resistant tuberculosis

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the October 2022 plenary meeting, a request for modification for bedaquiline (fumarate) for the treatment of multi-drug resistant tuberculosis.
The applicant requested to modify some key elements of Study 4.
Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable. Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0373/2020 of 9 September 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Dolutegravir / rilpivirine - EMEA-001750-PIP01-15-M06

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0524/2021 of 3 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Sulbactam / durlobactam - EMEA-002807-PIP01-20-M01

Entasis Therapeutics Inc.; Treatment of infections due to organisms of the *Acinetobacter baumannii-calcoaceticus* complex

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0499/2020 of 22 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Ataluren - Orphan - EMEA-000115-PIP01-07-M12

PTC Therapeutics International, Limited; Treatment of dystrophinopathy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes to discontinue Study 7 and to modify the subset of the paediatric population covered by the waiver could not be accepted.
The PDCO therefore adopted a negative opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0195/2021 of 10 May 2021). The details of the previously agreed PIP remain unchanged.

2.3.15. Binimetinib - EMEA-001454-PIP03-15-M02

Pierre Fabre Médicament; Treatment of melanoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could not be accepted.
The PDCO therefore adopted a negative opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0071/2018 of 16 March 2018). The details of the previously agreed PIP remain unchanged.
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Encorafenib - EMEA-001588-PIP01-13-M02

Pierre Fabre Médicament; Treatment of melanoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could not be

accepted.
The PDCO therefore adopted a negative opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0071/2018 of 16 March 2018).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. Isatuximab - EMEA-002205-PIP01-17-M03

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0185/2021 of 10 May 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Bilastine - EMEA-000347-PIP02-16-M04

Faes Farma S.A.; Treatment of allergic conjunctivitis

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

In the written response the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0526/2021 of 3 December 2021.

2.3.19. Sodium chloride solution 4.2% (w/v) / idrevloride, 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide - Orphan - EMEA-002935-PIP01-20-M02

Parion Sciences, Inc.; Treatment of primary ciliary dyskinesia (PCD)

Day 60 opinion

Pneumology – Allergology

Note: Withdrawal request received on 13 October 2022

2.3.20. Lanthanum carbonate hydrate - EMEA-000637-PIP02-10-M07

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of hyperphosphataemia

Day 60 opinion

Uro-nephrology

Summary of Committee discussion:

The Committee reviewed and discussed the applicant's argumentation for a modification of the PIP, including the new information received after Day 30 and including the assessors' comments, and concluded that the proposed changes are not agreeable.
All modifications are entirely retrospective; thus they would not serve any scientific or health-related purpose any longer. The majority of the proposals are not sufficiently justified either.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could not be accepted.
The PDCO therefore adopted a negative opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0303/2018 of 12 September 2018). The details of the previously agreed PIP remain unchanged.

2.3.21. Vosoritide - Orphan - EMEA-002033-PIP01-16-M03

BioMarin International Limited; Treatment of achondroplasia

Day 1 opinion

Other

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0051/2022 of 11 March 2022).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Baricitinib - EMEA-C3-001220-PIP03-16-M02

Eli Lilly and Company; Treatment of atopic dermatitis

Day 30 letter

Dermatology

2.7.2. Cabozantinib (S)-malate - EMEA-C2-001143-PIP01-11-M03

IPSEN Pharma; Treatment of malignant solid tumours

Day 30 letter

Oncology

2.7.3. Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA-C2-002330-PIP01-18-M02

Pfizer Europe MA EEIG; Prevention of disease caused by *Streptococcus pneumoniae*

Day 30 letter

Vaccines

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Obefazimod - EMEA-003196-PIP01-22

Treatment of ulcerative colitis / Treatment of Crohn’s disease

Day 90 discussion

Gastroenterology-Hepatology

3.1.2. Inclacumab - EMEA-003219-PIP01-22

Treatment of sickle cell disease

Day 90 discussion

Haematology-Hemostaseology

3.1.3. Dolutegravir / HIV-1 maturation inhibitor - EMEA-003152-PIP01-21

Treatment of human immunodeficiency virus (HIV-1) infection

Day 90 discussion

Infectious Diseases

3.1.4. HIV-1 maturation inhibitor - EMEA-003153-PIP01-21

Treatment of human immunodeficiency virus (HIV-1) infection

Day 90 discussion

Infectious Diseases

3.1.5. Posoleucel - Orphan - EMEA-002908-PIP01-20

AlloVir International DAC; Treatment of viral diseases in haematopoietic stem cell transplantation

Day 90 discussion

Infectious Diseases

3.1.6. Humanised monoclonal IgG1-based antibody - EMEA-003100-PIP01-21

Treatment of spinal muscular atrophy

Day 90 discussion

Neurology

3.1.7. Pridopidine (hydrochloride) - Orphan - EMEA-003174-PIP01-21

Prilenia Therapeutics B.V.; Treatment of Huntington disease (HD)

Day 90 discussion

Neurology

3.1.8. Vodobatinib - EMEA-003014-PIP01-21

Treatment of chronic myeloid leukaemia

Day 90 discussion

Oncology

3.1.9. Enzastaurin hydrochloride - Orphan - EMEA-003096-PIP02-22

Aytu BioPharma Inc.; Treatment of Ehlers-Danlos syndrome

Day 90 discussion

Other

3.1.10. Depemokimab - EMEA-003051-PIP04-22

Treatment of eosinophilic granulomatosis with polyangiitis (EGPA)

Day 90 discussion

Pneumology - Allergology

3.1.11. Stiripentol - Orphan - EMEA-003200-PIP01-22

Biocodex SA; Treatment of primary hyperoxaluria

Day 90 discussion

Uro-nephrology

3.1.12. Live, attenuated, dengue virus, serotype 4 (DENV4) / Live, attenuated, dengue virus, serotype 3 (DENV3) / Live, attenuated, chimeric dengue virus, serotype 2 (DENV2) / Live, attenuated, dengue virus, serotype 1 (DENV1) - EMEA-002999-PIP01-21

Prevention of dengue disease

Day 90 discussion

Vaccines

3.1.13. Soluble guanylate cyclase (sGC) stimulator - EMEA-003266-PIP01-22

Treatment of pulmonary arterial hypertension

Day 60 discussion

Cardiovascular Diseases

3.1.14. EMEA-002612-PIP02-22

Treatment of sickle cell disease

Day 60 discussion

Haematology-Hemostaseology

3.1.15. Efgartigimod alfa - EMEA-002597-PIP08-22

Treatment of dermatomyositis / Treatment of polymyositis (including antisynthetase

syndrome) / Treatment of immune-mediated necrotising myopathy

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.16. Albaconazole - EMEA-003279-PIP01-22

Treatment of vulvovaginal candidiasis

Day 60 discussion

Infectious Diseases

3.1.17. Asunercept - Orphan - EMEA-003201-PIP01-22

Apogenix AG; Treatment of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.18. Fosmanogepix - EMEA-003280-PIP01-22

Treatment of invasive fungal infections

Day 60 discussion

Infectious Diseases

3.1.19. Vilobelimab - EMEA-003080-PIP03-22

Treatment of severe coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.20. Ocrelizumab - EMEA-000310-PIP05-22

Treatment of multiple sclerosis

Day 60 discussion

Neurology

3.1.21. EMEA-003271-PIP01-22

Treatment of focal onset seizures

Day 60 discussion

Neurology

3.1.22. Adult differentiated autologous T cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z - EMEA-003264-PIP01-22

Treatment of acute lymphoblastic leukaemia

Day 60 discussion

Oncology

3.1.23. EMEA-003274-PIP01-22

Treatment of melanoma

Day 60 discussion

Oncology

3.1.24. Pembrolizumab / favezelimab - EMEA-003104-PIP02-22

Treatment of Hodgkin lymphoma

Day 60 discussion

Oncology

3.1.25. Pembrolizumab / vibostolimab - EMEA-003063-PIP02-22

Treatment of Hodgkin lymphoma

Day 60 discussion

Oncology

3.1.26. 1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one - Orphan - EMEA-003268-PIP01-22

Bridge Bio Europe B.V.; Treatment of pantothenate kinase-associated neurodegeneration

Day 60 discussion

Other

3.1.27. EMEA-002612-PIP03-22

Prevention of cardiopulmonary bypass (CPB)-induced postoperative pulmonary dysfunction

Day 60 discussion

Pneumology - Allergology

3.1.28. Immunoglobulin G4 [228-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal γ4-chain), disulphide with human monoclonal κ-chain, dimer /

immunoglobulin G4 [227-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal γ4-chain), disulphide with human monoclonal REGN5714 κ-chain, dimer / immunoglobulin G4 [224-proline], anti-(*Betula alleghaniensis* allergen Bet v 1) (human monoclonal γ4-chain), disulphide with human monoclonal κ-chain, dimer - EMEA-003270-PIP01-22

Treatment of allergic rhinitis with or without conjunctivitis in birch tree pollen allergic patients

Day 60 discussion

Pneumology - Allergology

3.1.29. EMEA-003276-PIP01-22

Treatment of post-traumatic stress disorder

Day 60 discussion

Psychiatry

3.1.30. Live attenuated respiratory syncytial virus (RSV) - EMEA-003277-PIP01-22

Prevention of respiratory syncytial virus (RSV) diseases

Day 60 discussion

Vaccines

3.1.31. MVA-BN-RSV - EMEA-003185-PIP01-22

Prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus RSV

Day 60 discussion

Vaccines / Infectious Diseases

3.1.32. Dexmedetomidine - EMEA-003283-PIP01-22

Sedation

Day 30 discussion

Anaesthesiology

3.1.33. Acetylsalicylic acid / rivaroxaban - EMEA-003291-PIP01-22

Prevention of atherothrombotic events

Day 30 discussion

Cardiovascular Diseases

3.1.34. Eplerenone / torasemide - EMEA-003289-PIP01-22

Treatment of heart failure

Day 30 discussion

Cardiovascular Diseases

3.1.35. Indapamide / valsartan - EMEA-003285-PIP01-22

Treatment of hypertension

Day 30 discussion

Cardiovascular Diseases

3.1.36. Rosuvastatin / fenofibrate - EMEA-003295-PIP01-22

Treatment of elevated cholesterol with elevated triglycerides

Day 30 discussion

Cardiovascular Diseases

3.1.37. Messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene - Orphan - EMEA-003298-PIP01-22

Intellia Therapeutics, Inc.; Treatment of transthyretin amyloidosis (ATTR)

Day 30 discussion

Cardiovascular Diseases / Neurology

3.1.38. EMEA-003286-PIP01-22

Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.1.39. Isotretinoin - EMEA-003303-PIP01-22

Treatment of congenital ichthyosis

Day 30 discussion

Dermatology

3.1.40. EMEA-003301-PIP01-22

Treatment of moderate to severe plaque psoriasis

Day 30 discussion

Dermatology

3.1.41. Spesolimab - EMEA-002475-PIP03-22

Treatment of Netherton syndrome

Day 30 discussion

Dermatology

3.1.42. EMEA-003299-PIP01-22

Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.43. EMEA-003299-PIP02-22

Treatment of obesity

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.44. Recombinant anti-RANKL fully human monoclonal antibody - EMEA-003293-PIP01-22

Treatment of bone loss associated with sex hormone ablative therapy / Prevention of skeletal related events in patients with bone metastases / Treatment of giant cell tumour of bone / Treatment of osteoporosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

Note: Withdrawal request received on 16 September 2022

3.1.45. Wharton's Jelly derived mesenchymal stromal cells - EMEA-003287-PIP01-22

Treatment of type 1 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.46. Crofelemer - Orphan - EMEA-003296-PIP01-22

Napo Therapeutics S.p.A.; Treatment of short bowel syndrome

Day 30 discussion

Gastroenterology-Hepatology

3.1.47. Dirloctocogene samoparvovec - Orphan - EMEA-003290-PIP01-22

Spark Therapeutics Ireland Limited; Treatment of haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.1.48. Mocravimod - Orphan - EMEA-003304-PIP01-22

Priothera SAS; Treatment in haematopoietic stem cell transplantation (HSCT)

Day 30 discussion

Haematology-Hemostaseology

3.1.49. Adintrevimab - EMEA-003118-PIP02-22

Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.50. Ensitrelvir - EMEA-003192-PIP01-22

Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.51. EMEA-003288-PIP01-22

Treatment of developmental and epileptic encephalopathies and other seizure syndromes

Day 30 discussion

Neurology

3.1.52. Eplontersen - EMEA-003294-PIP01-22

Treatment of transthyretin amyloidosis

Day 30 discussion

Neurology

3.1.53. Humanised VHH-type bispecific antibody against complement component 5 and serum albumin - EMEA-003302-PIP01-22

Treatment of acetylcholine receptor-antibody positive generalised myasthenia gravis

Day 30 discussion

Neurology

3.1.54. Vesleteplirsen - EMEA-003305-PIP01-22

Treatment of Duchenne muscular dystrophy

Day 30 discussion

Neurology

3.1.55. Obinutuzumab - Orphan - EMEA-001207-PIP06-22

Roche Registration GmbH; Prevention of cytokine release syndrome induced by anti CD20/CD3 antibodies

Day 30 discussion

Oncology

3.1.56. Unesbulin - Orphan - EMEA-003297-PIP01-22

PTC Therapeutics International; Treatment of soft tissue sarcoma

Day 30 discussion

Oncology

3.1.57. Cyanocobalamin / pyridoxine / thiamine / diclofenac - EMEA-003292-PIP01-22

Treatment of inflammatory pain / Treatment of inflammatory rheumatic diseases

Day 30 discussion

Pain / Immunology-Rheumatology-Transplantation

3.1.58. Humanised IgG4 monoclonal antibody against A proliferation-inducing ligand - Orphan - EMEA-003300-PIP01-22

Chinook Therapeutics, Inc.; Treatment of IgA nephropathy

Day 30 discussion

Uro-nephrology

3.1.59. SARS-CoV-2, 19nCoV-CDC-Tan-HB02 strain (inactivated) - EMEA-003203-PIP01-22

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines / Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

No item

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Baricitinib - EMEA-001220-PIP03-16-M03

Eli Lilly and Company Limited; Treatment of atopic dermatitis

Day 30 discussion

Dermatology

3.3.2. Dupilumab - EMEA-001501-PIP04-19-M02

Regeneron Ireland DAC; Treatment of eosinophilic esophagitis

Day 30 discussion

Gastroenterology-Hepatology

3.3.3. Linaclotide - EMEA-000927-PIP01-10-M07

AbbVie Deutschland GmbH & Co. KG; Treatment of functional constipation

Day 30 discussion

Gastroenterology-Hepatology

3.3.4. Odevixibat - Orphan - EMEA-002054-PIP03-20-M02

Albireo AB; Treatment of Alagille syndrome

Day 30 discussion

Gastroenterology-Hepatology

3.3.5. Upadacitinb - EMEA-001741-PIP02-16-M02

AbbVie Ltd; Treatment of ulcerative colitis

Day 30 discussion

Gastroenterology-Hepatology

3.3.6. (1R,2S,5S)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide - EMEA-003081-PIP01-21-M02

Pfizer Europe MA EEIG; Prevention of coronavirus disease 2019 (COVID-19) / Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.3.7. Doravirine - EMEA-001676-PIP01-14-M05

Merck Sharp & Dohme (Europe), Inc.; Treatment of human immunodeficiency virus-1 (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.8. Lefamulin - EMEA-002075-PIP01-16-M03

Nabriva Therapeutics DAC; Treatment of community-acquired pneumonia

Day 30 discussion

Infectious Diseases

3.3.9. Tecovirimat monohydrate - Orphan - EMEA-001205-PIP02-19-M02

SIGA Technologies, Inc.; Treatment of the following viral infections in adults and children with body weight at least 13 kg: smallpox, monkeypox, cowpox. Also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg

Day 30 discussion

Infectious Diseases

3.3.10. Tenofovir disoproxil fumarate / lamivudine / doravirine - EMEA-001695-PIP01-14-M05

Merck Sharp & Dohme (Europe), Inc.; Treatment of human immunodeficiency virus-1 (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.11. Givinostat - Orphan - EMEA-000551-PIP04-21-M01

Italfarmaco S.p.A.; Treatment of Duchenne muscular dystrophy

Day 30 discussion

Neurology

3.3.12. Ofatumumab - EMEA-002397-PIP01-18-M03

Novartis Ireland Limited; Treatment of multiple sclerosis

Day 30 discussion

Neurology

3.3.13. Siponimod (hemifumarate) - EMEA-000716-PIP01-09-M05

Novartis Europharm Ltd; Treatment of multiple sclerosis

Day 30 discussion

Neurology

3.3.14. Entospletinib - Orphan - EMEA-002058-PIP01-16-M01

Kronos Bio Inc.; Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology

3.3.15. Imetelstat - Orphan - EMEA-001910-PIP03-20-M01

Geron Corporation; Treatment of acute myeloid leukaemia (AML) / Treatment of myelodysplastic syndromes (MDS), including juvenile myelomonocytic leukaemia (JMML)

Day 30 discussion

Oncology

3.3.16. Lenvatinib - EMEA-001119-PIP03-19-M03

Eisai GmbH; Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer, follicular thyroid cancer and osteosarcoma

Day 30 discussion

Oncology

3.3.17. Characterised peanut powder - EMEA-001753-PIP02-15-M01

Cambridge Allergy Ltd; Treatment of peanut allergy

Day 30 discussion

Other

3.3.18. Setrusumab - Orphan - EMEA-002169-PIP01-17-M02

Mereo Biopharma 3 Ltd; Treatment of osteogenesis imperfecta

Day 30 discussion

Other

3.3.19. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of *Betula alba* pollen (birch pollen) - EMEA-000630-PIP02-09-M05

LETI Pharma GmbH; Treatment of allergic rhinitis / rhino-conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.20. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of birch pollen - EMEA-000837-PIP01-10-M02

LETI Pharma GmbH; Treatment of allergic rhinitis / rhino-conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.21. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of birch, alder and hazel pollen - EMEA-000662-PIP02-09-M05

LETI Pharma GmbH; Treatment of allergic rhinitis / rhino-conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.22. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of birch, alder and hazel pollen - EMEA-000838-PIP01-10-M02

LETI Pharma GmbH; Treatment of allergic rhinitis / rhino-conjunctivitis

Day 30 discussion

Pneumology - Allergology

3.3.23. Modified vaccinia Ankara - Bavarian Nordic virus (smallpox) - EMEA-001161-PIP02-11-M02

Bavarian Nordic A/S; Prevention of smallpox, monkeypox and disease caused by vaccinia virus

Day 30 discussion

Vaccines

3.3.24. COVID-19 vaccine (Ad26.COV2-S (recombinant)) - EMEA-002880-PIP01-20-M01

Janssen-Cilag International N.V.; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines / Infectious Diseases

3.3.25. BNT162b2 / tozinameran / famtozinameran - EMEA-002861-PIP02-20-M05

BioNTech Manufacturing GmbH; Prevention of coronavirus disease 2019 (COVID-19)

Day 8 discussion

Infectious Diseases

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of submissions of applications with start of procedure 17 October 2022 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. Plasmid expressing variant of human interleukin 10 - EMEA-18-2021

Xalud Therapeutics, Inc; All classes of medicinal products for treatment of primary and secondary osteoarthrosis / Treatment of moderate-to-severe pain and reduced function due to osteoarthritis; and modification of osteoarthritis disease

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No item

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO membership

The PDCO Committee noted the nomination of Maja Pavlovic as the new member of Croatia.

The PDCO Chair welcomed Jose Ignacio Malagon Calle representing Healthcare Professionals' Representative as the new Alternate Member.

9.1.2. Vote by Proxy

No item

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The list of PIP-related CHMP procedures starting in September 2022, was presented to the PDCO members.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Party: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The Vice-Chair of the Non-clinical Working Party (NcWP) identified the products which will require NcWP evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward (*ad ínterim*)

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients' and Consumers' Working Party (PCWP)/Healthcare Professionals' Working Party (HCPWP)

Summary of Committee discussion:

The Meeting Summary of PCWP/HCPWP joint meeting 22 September 2022, Meeting Summary of PCWP meeting 22 September 2022, Meeting Summary of HCPWP meeting 22 September 2022 and draft Agenda PCWP/HCPWP annual meeting with all eligible organisations to be held on 15 November 2022 were presented for information.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

Summary of Committee discussion:

The Committee members were informed of the outcomes of Enpr-EMA's annual meeting, which took place on 4th October 2022. A report from the meeting will be published in the near future.

9.5. Cooperation with International Regulators

9.5.1. Paediatric Cluster Teleconference

Summary of Committee discussion:

The September 2022 agenda and minutes of the cluster were shared with the PDCO members for information.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

9.7.1. Draft Workplan for 2023

PDCO Chair: Brian Aylward

Summary of Committee discussion:

The Committee discussed potential items for the PDCO workplan 2023.

9.8. Planning and reporting

No item

10. Any other business

10.1. COVID-19 update

Summary of Committee discussion:

The update was cancelled.

10.2. Introduction to the DARWIN EU® Coordination Centre

Summary of Committee discussion:

The presentation was given by the deputy director of the DARWIN EU® Coordination Centre. An update was provided on the DARWIN EU® establishment and use of RWE, and the available standard analyses. There were exchanges on how PDCO can request studies using DARWIN EU® and the suitability of the data sources to be onboarded in the network.

10.3. Online access to procedure data

Summary of Committee discussion:

Access to PDCO procedural data via Oracle BI (OBIEE, as interface to PedRA) was demonstrated. A presentation was made available to members.

10.4. Public consultation on Good Practice Guide for the use of the EU metadata catalogue

Summary of Committee discussion:

The group was informed about the current public consultation on Good Practice Guide for the use of the EU metadata catalogue. The catalogue will replace the current ENCePP catalogue, containing metadata on real-world data sources and studies. The overarching objective of the catalogue is to facilitate the discoverability of data sources to generate adequate evidence for regulatory purposes; for example the initial identification of data sources, or the assessment of the suitability of data sources proposed in studies or protocols. The Good Practice Guide provides recommendations to a variety of stakeholders for the use of the catalogue and describes the metadata elements that are envisaged to be within the catalogue. The public consultation is open until 16/11/2022 and comments should be sent to metadata@ema.europa.eu.

10.5. Public consultation on Data Quality Framework

Summary of Committee discussion:

The group was informed about the current public consultation on the draft Data Quality Framework. The objectives of the document are to improve consistency in the evaluation of the quality of the data used by regulators, enable the development of a standardised approach for data quality across all data sources, facilitate a more systematic use of data for regulatory decision-making, support the trust of stakeholders in the data that underpinned regulatory decisions. The Data Quality Framework provides general considerations that can be applied to a wide range of data sources for the purpose of characterising and assessing data quality for decision making. Outlines how to measure data quality in different scenarios where real-world data need to be used for regulatory decision-making. The document introduces an approach to evaluate the performance of the framework and the need for its improvement to support decision-making. It is intended to serve as an overarching framework from which more focused data quality recommendations can be derived for specific regulatory applications. It is produced in a collaborative process by EMA, HMA and Towards the European Health Data. The public consultation is open until 18/11/2022 and comments should be sent to dataqualityframework@ema.europa.eu.

11. Breakout sessions

11.1. Vaccines

Summary of Committee discussion:

The session was cancelled.

11.2. Paediatric oncology

Summary of Committee discussion:

The group was informed about the upcoming Accelerate meeting on DNA repair pathway inhibitors in paediatric cancers.

11.3. Neonatology

Summary of Committee discussion:

The group discussed plans for the revision of the neonatal guideline.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 11-14 October 2022 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brian Aylward	Chair	Ireland	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on: No participation in final deliberations and voting on:	2.1.2. Ruxolitinib (phosphate) - EMEA-002618-PIP03-21 2.2.7. Dabrafenib - EMEA-C-001147-PIP02-20 2.2.8. Trametinib - EMEA-C-001177-PIP02-20
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Maria Eleni Avraamidou	Alternate	Cyprus	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Louisa Braun Exner	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member (Vice-Chair)	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP alternate)	Hungary	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Dovile Zacharkiene	Member	Lithuania	No interests declared	
Olivier Moes	Alternate	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No participation in final deliberations and voting on:	3.3.4. Odevixibat - Orphan - EMEA-002054-PIP03-20-M02
Maaike van Dartel	Alternate	Netherlands	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No participation in discussion, final deliberations and voting on:	2.1.3. Sirolimus - Orphan - EMEA-003168-PIP01-21
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Kristin Karlsson	Member	Sweden	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jose Ignacio Malagon Calle	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Tomasz Grybek	Alternate	Patients' Organisation Representative	No interests declared	
David Khan	Expert - in person*	Sweden	No restrictions applicable to this meeting	
María Estela Moreno Martín	Expert - via telephone *	Spain	No interests declared	
Celine Chu	Expert - via telephone *	France	No interests declared	
Susanne Kaul	Expert - via telephone *	Germany	No interests declared	
Birgit Ahrens	Expert - via telephone *	Germany	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Lisbeth Barkholt	Expert - via telephone *	Sweden	No interests declared	
Helena Faust	Expert - via telephone *	Sweden	No interests declared	
Charlotta Bergquist	Expert - via telephone *	Sweden	No interests declared	
Meeting run with support from relevant EMA staff				
* Experts were evaluated against the agenda topics or activities they participated in				

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/